| 12-core prostate biopsy scheme | 19 |
| 5-hydroxyuracil incision | 45 |
| Adenocarcinoma | 196 |
| Adjuvant chemotherapy | 96 |
| Adjuvant intraluminal therapy | 129 |
| Adjuvant treatments | 264 |
| ADMA | 107 |
| Aging | 133 |
| AMACR/P504S | 92 |
| Anxiety | 7 |
| Arginine | 107 |
| Autologous stem-cell transplantation | 258 |
| Awareness month | 142 |
| Base excision repair | 45 |
| Benign prostatic hyperplasia | 71 |
| Bilateral | 56 |
| Biopsy | 15, 83 |
| Bladder | 179 |
| Bladder cancer | 34, 40, 107, 168, 174, 206, 264 |
| Breast cancer | 142 |
| Cancer | 133 |
| Cancer prognosis | 252 |
| Cancer-specific survival | 174 |
| Case report | 192 |
| Castration sensitive | 1 |
| Chemotherapy | 1, 67, 258 |
| Children | 200 |
| Chromophobe | 273 |
| Chromosome translocation | 122 |
| Chronic pyelonephritis | 192 |
| Cisplatin | 67 |
| Citrulline | 107 |
| Clinically insignificant prostate cancer | 19 |
| Clinically significant prostate cancer | 215 |
| Cognitive fusion | 15 |
| Colorectal malignancies | 179 |
| Comorbidity | 73 |
| Complication | 111 |
| Continence | 236 |
| Coronavirus | 206 |
| COVID-19 | 206 |
| Creatinine | 242 |
| Cystectomy | 168 |
| Detection | 11 |
| Diabetes mellitus | 162 |
| Eccrine porocarcinoma | 186 |
| Elderly | 73 |
| Emergency | 276 |
| Endoscopy | 236 |
| Epstein criteria | 19 |
| Fiducial marker | 158 |
| Geriatrics | 133 |
| Germ cell testicular cancer | 67 |
| Gleason grade | 26 |
| Glomerular filtration rates | 242 |
| Google trends | 142 |
| Granulomatous orchitis | 126 |
| Haematuria | 34 |
| Haematuria duration | 34 |
| Haematuria frequency | 34 |
| Health status | 73 |
| High-risk carcinoma | 219 |
| Histology | 236 |
| Hybrid tumor | 273 |
| Index lesion | 147 |
| Intravesical BCG | 206 |
| İrradiation | 219 |
| L-NMMA | 107 |
| Low-grade | 273 |
| Lymph node involvement | 174 |
| Lymphocyte | 168 |
| Lymphovascular invasion | 174 |
| Malignancy | 126 |
| Malignant eccrine poroma | 186 |
| Metachronous | 56 |
| Metachronous neoplasms | 49 |
| Metastasectomy | 270 |
| Metastases | 231 |
| Metastasis | 270 |
| Metformin | 162 |
| Mid-term follow-up | 117 |
| MiT family carcinomas | 122 |
| MRI US Fusion | 11 |
| MRI-ultrasound fusion | 210 |
| multiparametric magnetic resonance imaging | 15, 147 |
| Neoadjuvant chemotherapy | 264 |
| Neoadjuvant hormonal treatment | 219 |
| Neobladder | 236 |
| Nephrectomy volüme | 247 |
| Nephrometry score | 242 |
| Nephron-sparing surgery | 247 |
| Neutrophil | 168 |
| Non-muscle-invasive bladder cancer | 45 |
| Non-tumor factors | 247 |
| Non-urothelial bladder carcinomas | 96 |
| Oncocytic tumor | 273 |
| Oncological outcomes | 96 |
| Overall survival | 174, 252 |
| Pain score | 7 |
| Pandemic | 206 |
| Paratesticular rhabdomyosarcoma | 200 |
| Partial cystectomy | 196 |
| Partial nephrectomy | 111, 242 |
| Pediatric | 189 |
| Peritoneal metastases | 179 |
| PI-RADS | 147 |
| Poroid neoplasm | 186 |
| Positive surgical margin | 26 |
| Predictors | 111 |
| Preoperative | 276 |
| Progression | 40, 45 |
| Prostate biopsy | 11, 87, 138, 210 |
| Prostate cancer | 1, 11, 19, 83, 87, 92, 73, 142, 153, 158, 162, 210, 219, 225, 231, 264, 270 |
| Prostate neoplasms | 147 |
| Prostate-specific antigen | 215 |
| PSA | 92 |
| PSA density | 215 |
| Questionnaire | 133 |
| Radical cystectomy | 96 |
| Radical inguinal orchiectomy | 200 |
| Radical nephrectomy | 276 |
| Radical prostatectomy | 19, 26, 87, 147, 219, 225, 231, 280 |
| Radiotherapy | 158, 162, 225, 258 |
| Recurrence | 40, 270 |
| Recurrence-free survival | 231 |
| Renal cell cancer | 111 |
| Renal cell carcinoma | 49, 117, 122, 186, 247, 273 |
| Renal mass | 192 |
| Renal tumor | 242 |
| Renal-sparing approach | 129 |
| Resection | 179 |
| Resection technique | 111 |
| Retropubic radical prostatectomy | 153 |
| Risk factors | 40 |
| Robotic assisted laparoscopic prostatectomy | 71 |
| Robotic prostatectomy | 153 |
| Robotic surgery | 71, 280 |
| Rupture | 276 |
| SDMA | 107 |
| Seconder primary malignant tumour | 49 |
| Sertoliform cystadenoma | 189 |
| Sexual function | 138 |
| Side effects | 162 |
| Signet-ring cell carcinoma | 196 |
| Spontaneous | 276 |
| Standard biopsy prostate cancer | 15 |
| Stereotactic | 158 |
| Stroke | 67 |
| Surgical margin positivity | 231 |
| Surgical technique | 153 |
| Surgical treatment | 247 |
| Survival | 117 |
| Sweat gland tumour | 186 |
| Synchronous | 56 |
| Synchronous neoplasms | 49 |
| Systemic immune-inflammation index | 252 |
| Targeted biopsy | 11, 210 |
| Testicle | 126 |
| Testicular cancer | 252, 264 |
| Testicular dysgenesis syndrome | 56 |
| Testicular germ cell tumors | 258 |
| Testicular germ cell tumour | 56 |
| Testis tumors | 200 |
| Testis-sparing surgery | 189, 200 |
| Thromboembolism | 67 |
| Translocation renal cell carcinoma | 122 |
| Transrectal ultrasound-guided prostate biopsy | 7 |
| Treatment | 1 |
| Unclassified renal cell carcinoma | 117 |
| Upgrading | 87 |
| Upper urinary tract urethelial tumor | 129 |
| Ureter | 179 |
| Urinary bladder | 196 |
| Urodynamic | 236 |
| Urological cancers | 280 |
| Ventriculoperitoneal shunt | 280 |
| Visual analog score | 138 |
| Vitamin D | 83 |
| Wilms tumor | 276 |
| Xp11 translocation | 122 |
| Yolk sac tumor | 200 |